Clinical Trials Logo

Citation(s)

A Phase 3, Open-Label Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Lumacaftor in Combination With Ivacaftor in Subjects 6 Through 11 Years of Age With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation

Details for clinical trial NCT01897233